8-K: Tonix Pharmaceuticals Announces Positive Market Assessment for Fibromyalgia Drug Tonmya

Tonix Pharmaceuticals reports a favorable market assessment for its fibromyalgia drug candidate, Tonmya, with a potential NDA submission in the second half of 2024.

Summary

• Tonix Pharmaceuticals announced that EVERSANA completed an initial market assessment for Tonmya, a potential treatment for fibromyalgia.
• The assessment indicates that approximately 2.7 million adults in the U.S. are diagnosed and treated for fibromyalgia, with 90% being female.
• Current treatments include FDA-approved drugs like duloxetine (23%), pregabalin (13%), and milnacipran (1%), as well as off-label drugs such as gabapentin (26%) and opioids like hydrocodone (20%).
• A significant 85% of fibromyalgia patients fail first-line therapy, and 79% are on multiple therapies.
• Physicians showed a median interest of 4.0 out of 5 in Tonmya as a new treatment option and indicated a potential use in 40% of their fibromyalgia patients, assuming no market access barriers.
• Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 and anticipates an FDA decision on approval in 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Tonmya, supported by strong market research and clinical trial results. The high physician interest and unmet need in the fibromyalgia market contribute to a favorable sentiment.

Positives

• Tonmya has shown statistically significant results in two Phase 3 trials, reducing pain and improving sleep and fatigue.
• Physicians have expressed a high level of interest in Tonmya as a new treatment option.
• Tonmya is a non-opioid, centrally-acting medication, addressing a need for alternatives to addictive opioids.
• The market assessment indicates a large unmet need for effective fibromyalgia treatments.
• The company is on track to submit an NDA in the second half of 2024.
• Tonmya is designed for long-term daily bedtime use and targets non-restorative sleep.
• Tonmya is not associated with the common side effects of other FDA-approved fibromyalgia medications.
• Medicare patients stand to benefit from a decrease in out-of-pocket prescription drug liability to $2,000 per year in 2025.

Negatives

• A high percentage of fibromyalgia patients fail first-line therapy, indicating a need for more effective treatments.
• Many patients are currently prescribed off-label drugs, including opioids, which have known risks.
• There is a high level of dissatisfaction with currently prescribed drugs for fibromyalgia.
• 79% of fibromyalgia patients are on multiple therapies, suggesting that current treatments are not fully effective.

Risks

• The company faces risks related to obtaining FDA approval for Tonmya.
• There are risks associated with the commercialization of any new product.
• The company may require additional financing.
• There are uncertainties related to patent protection and litigation.
• There are uncertainties related to government or third-party payor reimbursement.
• The company faces substantial competition in the pharmaceutical market.
• There are risks associated with the development, regulatory approval, and commercialization of new products.

Future Outlook

Tonix anticipates submitting an NDA for Tonmya in the second half of 2024 and expects an FDA decision on approval in 2025. The company also plans to refine its business strategy for the anticipated launch of Tonmya in 2025.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the research provides valuable insights and informs the vision for the commercialization of Tonmya.
• Dr. Lederman mentioned they were surprised to learn that opioids dominate the fibromyalgia prescription market despite the known risks of dependency.
• Dr. Lederman believes that Tonmya can provide a non-opioid, centrally-acting solution for fibromyalgia patients.

Industry Context

This announcement is significant as it highlights the unmet need for effective fibromyalgia treatments and the potential for Tonmya to address this need. The high prevalence of off-label opioid use underscores the importance of non-addictive alternatives. The market research suggests a strong interest from physicians in new treatment options, which could position Tonmya favorably upon approval.

Comparison to Industry Standards

• The document highlights that 85% of fibromyalgia patients fail first-line therapy, which is consistent with the challenges in treating this condition.
• The three FDA-approved drugs for fibromyalgia, pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella), are mentioned, and the document notes that patients often rotate between these drugs and are on multiple therapies, indicating a lack of a single effective solution.
• The document notes that opioids are prescribed more frequently than FDA-approved drugs, which is a concern given the risks of dependency. This is a common issue in pain management, where opioids are often used despite their drawbacks.
• The document mentions that the median interest in Tonmya among physicians is 4.0 on a 5-point scale, and they intend to use it in 40% of their patients, which is a strong indication of potential market adoption compared to other new drugs in the space.
• The document compares Tonmya to other fibromyalgia drugs, noting that it has activity in pain, sleep, and fatigue, and is not associated with the common side effects of other FDA-approved medications. This is a key differentiator compared to drugs like Cymbalta, Savella, and Lyrica, which have known tolerability issues.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of Tonmya.
• Patients with fibromyalgia may have a new, effective treatment option.
• Physicians may have a new tool to manage fibromyalgia patients.
• Employees of Tonix may benefit from the company's growth and success.

Next Steps

• Tonix plans to have a Type B pre-NDA meeting with the FDA in the second quarter of 2024.
• The company intends to submit an NDA to the FDA for Tonmya in the second half of 2024.
• Tonix expects an FDA decision on the NDA approval in 2025.
• The company will refine its business strategy for the anticipated launch of Tonmya in 2025.

Key Dates

Keywords

Tonmya, fibromyalgia, TNX-102 SL, EVERSANA, NDA, opioids, pain management, clinical trials, FDA, central nervous system, non-opioid, sublingual, cyclobenzaprine, market assessment, prescription drugs